← Back to Search

Other

Zio®XT Monitor Arm for Atrial Fibrillation (GUARD-AF Trial)

Phase 4
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 2.5 years to 5 years after study start
Awards & highlights

GUARD-AF Trial Summary

This trial will test if a detection intervention for atrial fibrillation or atrial flutter can reduce the incidence of stroke in people over 70.

Eligible Conditions
  • Atrial Fibrillation
  • Atrial Flutter

GUARD-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 2.5 years to 5 years after study start
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 2.5 years to 5 years after study start for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of all strokes leading to hospitalization
Incidence of bleeding leading to hospitalization

GUARD-AF Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Zio®XT Monitor ArmExperimental Treatment1 Intervention
Group II: Usual Care ArmActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,638 Previous Clinical Trials
4,116,583 Total Patients Enrolled
72 Trials studying Atrial Fibrillation
1,635,437 Patients Enrolled for Atrial Fibrillation
PfizerIndustry Sponsor
4,567 Previous Clinical Trials
10,899,942 Total Patients Enrolled
46 Trials studying Atrial Fibrillation
652,839 Patients Enrolled for Atrial Fibrillation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies for people to join this clinical experiment?

"According to clinicaltrials.gov, the initial posting for this medical trial was on December 17th 2019 and its last update occurred on November 17th 2022; as a result, it is not presently seeking candidates. However, 482 other studies are currently welcoming participants."

Answered by AI

How many locations are currently conducting this research endeavor?

"This investigation is recruiting up to 100 patients from Local Institution - 0132 in Palm Harbor, Local Institution - 0005 in Detroit, and Local Institution - 0345 in Evergreen Park along with several other clinics."

Answered by AI

What potential adverse effects could patients face from this treatment?

"Powered's experts rated the safety of this intervention a 3, due to its approval status as part of Phase 4 clinical trials."

Answered by AI

Who else is applying?

What state do they live in?
Texas
Alabama
California
Other
What site did they apply to?
Mission Cardiovascular Research Institute
Local Institution
Western Washington Medical Group
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
3+
1

Why did patients apply to this trial?

I would like to see my A-Fib gone.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

What would be the time commitment? Is there compensation? Parking?
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke
2019. "A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04126486.
~2237 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top